Amitriptyline reconsidered : the relevance of dosage regimen, serum concentrations, genotypic measures and adverse outcomes

Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/65725

Title:	Amitriptyline reconsidered : the relevance of dosage regimen, serum concentrations, genotypic measures and adverse outcomes
Authors:	Mifsud Buhagiar, Luana Serracino-Inglott, Anthony Azzopardi, Lilian M. LaFerla, Godfrey
Keywords:	Psychotropic drugs -- Administration Pain -- Treatment Central pain Psychotropic drugs -- Side effects
Issue Date:	2020
Publisher:	University of Malta. Department of Pharmacy
Citation:	Mifsud Buhagiar, L., Serracino-Inglott, A., Azzopardi, L. M., & LaFerla, G. (2020). Amitriptyline reconsidered : the relevance of dosage regimen, serum concentrations, genotypic measures and adverse outcomes. American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting & Exhibition.
Abstract:	Tricyclic antidepressants have played leading roles in psychiatric pharmacotherapy, with amitriptyline credited in the management of depression, and later also in neuropathic pain. It is accepted clinical practice to initiate therapy at a low dose, adjusting gradually to support tolerability. Exposure to amitriptyline and its metabolites is influenced by genetic polymorphisms of the cytochrome P450 subfamily enzymes1 , particularly CYP2C19 and CYP2D6. Evaluating the interplay between adverse outcomes and serum concentrations, as may be moderated by the dosage regimen and genotype-inferred variability on individual pharmacokinetics, should enable better informed use of this established drug
URI:	https://www.um.edu.mt/library/oar/handle/123456789/65725
Appears in Collections:	Scholarly Works - FacM&SPha

Files in This Item:

File	Description	Size	Format
Amitriptyline reconsidered The relevance of dosage regimen, serum concentrations, genotypic measures and adverse outcomes.pdf		694.46 kB	Adobe PDF	View/Open

Show full item record Statistics